These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 17192294)

  • 1. Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity.
    Chernausek SD; Backeljauw PF; Frane J; Kuntze J; Underwood LE;
    J Clin Endocrinol Metab; 2007 Mar; 92(3):902-10. PubMed ID: 17192294
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant insulin-like growth factor (IGF)-I treatment in short children with low IGF-I levels: first-year results from a randomized clinical trial.
    Midyett LK; Rogol AD; Van Meter QL; Frane J; Bright GM;
    J Clin Endocrinol Metab; 2010 Feb; 95(2):611-9. PubMed ID: 19880790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetic studies of recombinant human insulin-like growth factor I (rhIGF-I)/rhIGF-binding protein-3 complex administered to patients with growth hormone insensitivity syndrome.
    Camacho-Hübner C; Rose S; Preece MA; Sleevi M; Storr HL; Miraki-Moud F; Minuto F; Frystyk J; Rogol A; Allan G; Sommer A; Savage MO
    J Clin Endocrinol Metab; 2006 Apr; 91(4):1246-53. PubMed ID: 16403822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin-like growth factor-I deficiency in children with growth hormone insensitivity: current and future treatment options.
    Kemp SF
    BioDrugs; 2009; 23(3):155-63. PubMed ID: 19627167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Therapy for 6.5-7.5 years with recombinant insulin-like growth factor I in children with growth hormone insensitivity syndrome: a clinical research center study.
    Backeljauw PF; Underwood LE;
    J Clin Endocrinol Metab; 2001 Apr; 86(4):1504-10. PubMed ID: 11297575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two-year treatment of growth hormone (GH) receptor deficiency with recombinant insulin-like growth factor I in 22 children: comparison of two dosage levels and to GH-treated GH deficiency.
    Guevara-Aguirre J; Rosenbloom AL; Vasconez O; Martinez V; Gargosky SE; Allen L; Rosenfeld RG
    J Clin Endocrinol Metab; 1997 Feb; 82(2):629-33. PubMed ID: 9024266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Insulin-like growth factor-I treatment in primary growth hormone insensitivity: effect of recombinant human IGF-I (rhIGF-I) and rhIGF-I/rhIGF-binding protein-3 complex.
    Tonella P; Flück CE; Mullis PE
    Horm Res Paediatr; 2010; 73(2):140-7. PubMed ID: 20190552
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged treatment with recombinant insulin-like growth factor-I in children with growth hormone insensitivity syndrome--a clinical research center study. GHIS Collaborative Group.
    Backeljauw PF; Underwood LE
    J Clin Endocrinol Metab; 1996 Sep; 81(9):3312-7. PubMed ID: 8784089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Growth response to rhIGF-I 80 microg/kg twice daily in children with growth hormone insensitivity syndrome: relationship to severity of clinical phenotype.
    Azcona C; Preece MA; Rose SJ; Fraser N; Rappaport R; Ranke MB; Savage MO
    Clin Endocrinol (Oxf); 1999 Dec; 51(6):787-92. PubMed ID: 10619985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, double blind, placebo-controlled trial on safety and efficacy of recombinant human insulin-like growth factor-I in children with growth hormone receptor deficiency.
    Guevara-Aguirre J; Vasconez O; Martinez V; Martinez AL; Rosenbloom AL; Diamond FB; Gargosky SE; Nonoshita L; Rosenfeld RG
    J Clin Endocrinol Metab; 1995 Apr; 80(4):1393-8. PubMed ID: 7536209
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of insulin-like growth factor I (IGF-I) therapy on body composition and insulin resistance in IGF-I gene deletion.
    Woods KA; Camacho-Hübner C; Bergman RN; Barter D; Clark AJ; Savage MO
    J Clin Endocrinol Metab; 2000 Apr; 85(4):1407-11. PubMed ID: 10770174
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant human growth hormone plus recombinant human insulin-like growth factor-1 coadministration therapy in short children with low insulin-like growth factor-1 and growth hormone sufficiency: results from a randomized, multicenter, open-label, parallel-group, active treatment-controlled trial.
    Backeljauw PF; Miller BS; Dutailly P; Houchard A; Lawson E; Hale DE; Reiner B; Sperling MA;
    Horm Res Paediatr; 2015; 83(4):268-79. PubMed ID: 25765099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mecasermin rinfabate: insulin-like growth factor-I/insulin-like growth factor binding protein-3, mecaserimin rinfibate, rhIGF-I/rhIGFBP-3.
    Drugs R D; 2005; 6(2):120-7. PubMed ID: 15777106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant IGF-I: Past, present and future.
    Bright GM
    Growth Horm IGF Res; 2016 Jun; 28():62-5. PubMed ID: 26822565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of recombinant human insulin-like growth factor I (IGF-I) therapy on the growth hormone-IGF system of a patient with a partial IGF-I gene deletion.
    Camacho-Hübner C; Woods KA; Miraki-Moud F; Hindmarsh PC; Clark AJ; Hansson Y; Johnston A; Baxter RC; Savage MO
    J Clin Endocrinol Metab; 1999 May; 84(5):1611-6. PubMed ID: 10323388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin-like growth factor-I treatment of children with Laron syndrome (primary growth hormone insensitivity).
    Laron Z
    Pediatr Endocrinol Rev; 2008 Mar; 5(3):766-71. PubMed ID: 18367997
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recombinant human insulin-like growth factor I has significant anabolic effects in adults with growth hormone receptor deficiency: studies on protein, glucose, and lipid metabolism.
    Mauras N; Martinez V; Rini A; Guevara-Aguirre J
    J Clin Endocrinol Metab; 2000 Sep; 85(9):3036-42. PubMed ID: 10999782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of severe primary IGF-1 deficiency using rhIGF-1 preparation - first three years of Polish experience.
    Petriczko E; Jackowski T; Horodnicka-Józwa A; Wikiera B; Noczyńska A; Korpal-Szczyrska M; Birkholz-Walerzak D; Małecka-Tendera E; Kalina-Fraska B; Kalina M; Barg E; Beń-Skowronek I; Szewczyk L; Hilczer M; Smyczyńska J; Stawerska R; Lewiński A; Ziora K; Bossowski A; Pietrewicz E; Pyrżak B; Kędzia A; Szalecki M; Kilian A; Walczak M
    Endokrynol Pol; 2019; 70(1):20-27. PubMed ID: 30351442
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant human insulin-like growth factor-I therapy for children with growth disorders.
    Richmond EJ; Rogol AD
    Adv Ther; 2008 Dec; 25(12):1276-87. PubMed ID: 19066756
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of recombinant human insulin-like growth factor-I in treating children with short stature.
    Collett-Solberg PF; Misra M;
    J Clin Endocrinol Metab; 2008 Jan; 93(1):10-8. PubMed ID: 18165284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.